Metraipolis › archive › dc_7224d0cb5dfe

Favorable outcome of immunotherapy use in metastatic HR+/HER2- breast cancer: a population-based cohort study — Europe PMC PMID:40990681

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40990681
DOI
10.1097/js9.0000000000003556
License (as archived)
solo-consultazione
Archived
2026-11-09T19:30:42.968Z
SHA-256 of the archived text
7205621d4828144cd4acc77c88c520a409baa06011a134fcbe4520a7d66ea7bf
Stable URL of this page
https://metraipolis.com/documento/dc_7224d0cb5dfe

How to cite

Favorable outcome of immunotherapy use in metastatic HR+/HER2- breast cancer: a population-based cohort study — Europe PMC PMID:40990681 — Europe PMC (en), https://europepmc.org/article/MED/40990681 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7224d0cb5dfe (Metraipolis archive dc_7224d0cb5dfe, sha256 7205621d4828144cd4acc77c88c520a409baa06011a134fcbe4520a7d66ea7bf)
BibTeX
@misc{dc7224d0cb5dfe,
  title = {Favorable outcome of immunotherapy use in metastatic HR+/HER2- breast cancer: a population-based cohort study — Europe PMC PMID:40990681},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40990681},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7224d0cb5dfe; sha256 7205621d4828144cd4acc77c88c520a409baa06011a134fcbe4520a7d66ea7bf},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40990681. Agents can read the archived copy with the MCP tool read_document.